Reported positive (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Human · observational · Limited evidence · Dec 2024
Trastuzumab-Deruxtecan (T-Dxd)
Evidence at a glanceHuman · observationalMixed results⚠ Studies disagree
2 published studies tagged to this agent2 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?
Human · observational — Human observational evidence only — no trials.
- 2 human · 0 animal · 0 lab · 0 review/other
- Most authoritative study: HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract
- Studies disagree on the reported direction (conflict flagged).
- Findings conflict across studies
- All studies are small (n < 30)
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedtrastuzumab-deruxtecan (t-dxd)
Educational only, not medical advice. OncoForge makes no claim that Trastuzumab-Deruxtecan (T-Dxd) treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Cervical Neoplasms1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Endometrial Neoplasms1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
High Grade Serous Ovarian Carcinoma1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Mesonephric Adenocarcinoma (Cervix)11——
- HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract Human · observationalMixed results
Mesonephric Like Adenocarcinoma (Endometrium)11——
- HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract Human · observationalMixed results
Mesonephric Like Adenocarcinoma (Ovary)11——
- HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract Human · observationalMixed results
Mucinous Ovarian Carcinoma1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Ovarian Carcinosarcoma1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Ovarian Neoplasms1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Squamous Cervical Carcinoma1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Uterine Carcinosarcoma1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Uterine Leiomyosarcoma1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Uterine Serous Carcinoma1———
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observationalReported positive
Reported figures
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline0
Meta-analysis0
Systematic review0
Randomized trial0
Clinical trial0
Observational2
Case report0
Review0
Preclinical0
Other0
2 studies2 human
Tracking 2 published studies of Trastuzumab-Deruxtecan (T-Dxd): 2 in humans.
Reported direction across studies: 1 positive, 1 mixed.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Trastuzumab-Deruxtecan (T-Dxd) works.
Cancers named in these studies
mesonephric adenocarcinoma (cervix) (1)mesonephric-like adenocarcinoma (endometrium) (1)mesonephric-like adenocarcinoma (ovary) (1)endometrial neoplasms (1)ovarian neoplasms (1)cervical neoplasms (1)uterine carcinosarcoma (1)uterine leiomyosarcoma (1)uterine serous carcinoma (1)ovarian carcinosarcoma (1)
Conflicting evidence
Negative or mixed (1)
- HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract
Human · observational · Limited evidence · May 2026
All studies
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 21
HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · May 2026
Trastuzumab-deruxtecan-t-dxdmesonephric adenocarcinoma (cervix)mesonephric-like adenocarcinoma (endometrium)mesonephric-like adenocarcinoma (ovary)
The authors measured HER2 and FOLR1 protein expression by immunohistochemistry in 21 mesonephric and mesonephric-like gynecologic adenocarcinomas (13 endometrial, 5 ovarian, 3 cervical). HER2 was detectable in 14 of 21 tumors (two cases scored 2+ and many scored 1+, with no 3+ cases), while FOLR1 met MIRV eligibility in one case and ten additional tumors had 5–70% expression. Most tumors did not meet current thresholds for HER2- or FOLR1-targeted monotherapy, but the authors suggest detectable expression could justify exploring T-Dxd and MIRV combinations in selected cases.
Reported effects: Total cases assessed 21 · endometrial cases 13, n=21 · +9 more
Studied with: trastuzumab deruxtecan + mirvetuximab soravtansine.
Key findings
- HER2 expression was present in 14/21 tumors.
- HER2 (2+) was seen in two cases by both EC and GaC criteria; no HER2 (3+) was identified.
- Twelve other cases showed HER2 (1+) by endometrial cancer (EC) criteria; only four met 1+ by GaC criteria.
- FOLR1 met current MIRV treatment criteria in one case; ten other cases showed FOLR1 expression ranging from 5% to 70%.
- Most tumors did not meet current biomarker thresholds for trastuzumab (HER2) or MIRV monotherapy.
Limitations: Small sample size (21 cases).; Observational immunohistochemical study of archival tumors only — no treatment or clinical outcome data provided.; Heterogeneous primary sites (cervix, endometrium, ovary) which may affect biomarker distribution.; Use of different scoring criteria (EC vs GaC) produced discordant HER2 categorization, which may limit generalizability..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalReported positiveLimited evidenceTier 3 · early humann = 10
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
BMC cancer · Dec 2024 · retrospective cohort
Trastuzumab-deruxtecan-t-dxdTrastuzumab-deruxtecanendometrial neoplasmsovarian neoplasmscervical neoplasmsuterine carcinosarcomauterine leiomyosarcomauterine serous carcinomaovarian carcinosarcomahigh-grade serous ovarian carcinomamucinous ovarian carcinomasquamous cervical carcinoma
This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.
Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 · partial responses 5, n=10 · +2 more
Key findings
- 10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
- Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
- Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
- HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
- Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
- Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
- Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
- Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
- Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Trastuzumab-Deruxtecan (T-Dxd)'s evidence base, and anything that's been retracted.
Recently added- HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract Human · observational · added Jul 2026
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · added Jun 2026
Cancers where Trastuzumab-Deruxtecan (T-Dxd) reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Human evidence
Endometrial neoplasms1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Ovarian neoplasms1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Cervical neoplasms1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Human · observational · Dec 2024
Evidence at a glance: Trastuzumab-Deruxtecan (T-Dxd) by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Cervical neoplasmsHuman · observationalReported positive1 human
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Endometrial neoplasmsHuman · observationalReported positive1 human
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: endometrial cases 13, n=21 PMID 42095344 · effect sizes 0–21 across 11 studies
Most authoritative study: HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract
Based on a single study.
Mesonephric-like adenocarcinoma (endometrium)Human · observationalMixed results1 human
Human observational evidence only — no trials.
Largest credible effect: endometrial cases 13, n=21 PMID 42095344 · effect sizes 0–21 across 11 studies
Most authoritative study: HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract
Based on a single study.
Mesonephric-like adenocarcinoma (ovary)Human · observationalMixed results1 human
Human observational evidence only — no trials.
Largest credible effect: endometrial cases 13, n=21 PMID 42095344 · effect sizes 0–21 across 11 studies
Most authoritative study: HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Ovarian neoplasmsHuman · observationalReported positive1 human
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies
Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Trastuzumab-Deruxtecan (T-Dxd) depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies- Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies 5.4 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity · Human · observational · Dec 2024
Trials studying Trastuzumab-Deruxtecan (T-Dxd)
Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.